Orally Disintegrating Tablet Excipient Sales

Orally Disintegrating Tablet Excipient Sales Market Outlook

The globally valued Orally Disintegrating Tablet (ODT) excipient market is projected to reach approximately USD 1.5 billion by 2035, with a Compound Annual Growth Rate (CAGR) of 6.5% during the forecast period from 2025 to 2035. The surge in demand for innovative drug delivery systems, driven by the increasing prevalence of chronic diseases and the aging population, is a significant growth factor for this market. Moreover, the convenience offered by ODTs in terms of ease of administration and patient compliance has led to their rising popularity among pharmaceutical companies. The ongoing advancements in excipient technology, particularly in the development of superdisintegrants and taste-masking agents, are also propelling market growth. As the healthcare industry continually seeks to improve patient adherence to medications, the importance of ODT excipients as a critical component in drug formulation cannot be overstated.

Growth Factor of the Market

The growth of the orally disintegrating tablet excipient market is fundamentally driven by the increasing demand for patient-friendly medication forms, particularly among pediatric and geriatric populations, who may struggle to swallow traditional tablets. As pharmaceutical manufacturers focus on enhancing the bioavailability of active pharmaceutical ingredients (APIs), ODTs have emerged as a feasible solution that minimizes the need for water intake. Additionally, the rise of personalized medicine has led to the development of tailored ODT formulations, further expanding the market's potential. The growing trend of self-medication, coupled with the rising incidence of mental health disorders which typically require easy-to-administer medications, supports market expansion. Furthermore, the increasing adoption of ODTs in nutraceutical and dietary supplements correlates with a broader consumer trend toward convenience and user-friendly health products.

Key Highlights of the Market

• The increasing prevalence of chronic diseases is driving demand for effective and user-friendly drug delivery systems.
• The market is witnessing technological advancements in excipient formulations, particularly in superdisintegrants.
• Growing awareness and acceptance of self-medication are further propelling the adoption of ODTs.
• Regional expansion, particularly in emerging markets, is creating new opportunities for market players.
• Rising investments in R&D by pharmaceutical companies are leading to innovations in ODT excipients.

By Type

Superdisintegrants:

Superdisintegrants play a crucial role in the formulation of orally disintegrating tablets by ensuring rapid disintegration upon contact with moisture. These excipients enhance the dissolution rate of the active pharmaceutical ingredients by promoting a swift breakdown of the tablet matrix, thus improving bioavailability. Common superdisintegrants such as sodium starch glycolate and croscarmellose sodium are extensively utilized due to their efficiency and compatibility with various other excipients. The rising demand for superdisintegrants is primarily driven by their increasing application in the pharmaceutical industry, particularly for medications designed for patients who may face difficulties in swallowing. The continuous innovations in superdisintegrant formulations further bolster their market presence, making them a key segment in the ODT excipient market.

Binders:

Binders are essential components in the formulation of orally disintegrating tablets, as they provide the necessary cohesion to the tablet ingredients, thus maintaining tablet integrity during manufacturing and storage. Various binder materials, including natural polymers like starch and synthetic polymers such as polyvinylpyrrolidone, are employed based on their specific binding properties and the desired characteristics of the final product. The choice of binder can significantly influence the disintegration time and overall performance of the ODT. As the demand for customized and patient-friendly formulations grows, the market for binders in the ODT sector is also expected to expand, driven by the increasing focus on improving patient compliance and medication efficacy.

Fillers:

Fillers are often utilized in ODT formulations to achieve the required tablet weight and volume while enhancing the overall texture and mouthfeel of the product. Commonly used fillers include lactose, mannitol, and microcrystalline cellulose, each chosen for their specific properties that contribute to the tablet's performance. The demand for fillers in ODTs is largely driven by the growing trend toward low-calorie and sugar-free formulations, particularly in the nutraceutical market. The selection of fillers also affects the taste and stability of the tablet, with a continued emphasis on formulating products that are not only effective but also palatable for consumers. As a result, the filler segment remains a vital component in the overall ODT excipient market.

Lubricants:

Lubricants are another critical category of excipients used in the manufacturing of orally disintegrating tablets, primarily to prevent sticking during the compression process and to enhance the flowability of the powder blend. Magnesium stearate is the most commonly used lubricant owing to its effectiveness and compatibility with various excipients. The presence of lubricants plays a significant role in ensuring uniformity in tablet weight and density, which ultimately impacts the disintegration and dissolution characteristics. As the ODT market continues to expand, the importance of lubricants in maintaining the quality and consistency of tablet production becomes increasingly clear, supporting the growth of this segment.

Sweeteners:

Sweeteners are essential to the formulation of orally disintegrating tablets, particularly for improving the taste and palatability of medications, which is crucial in enhancing patient compliance. Natural and artificial sweeteners, such as sucralose, aspartame, and stevia, are commonly used to mask the unpleasant flavors of active pharmaceutical ingredients. The rising consumer demand for flavored and pleasant-tasting medications is propelling the sweetener segment within the ODT excipient market. As pharmaceutical companies strive to create formulations that appeal to a broader audience, especially for pediatric and geriatric patients, the role of sweeteners becomes increasingly vital in ensuring the success of ODT products.

By End Use

Pharmaceuticals:

The pharmaceutical sector represents the largest end-use segment for orally disintegrating tablet excipients, driven by the increasing need for novel drug delivery systems that enhance patient compliance and medication efficacy. ODTs are particularly beneficial for patients with swallowing difficulties, such as the elderly and children, and are increasingly being employed in the formulation of a wide range of therapeutic agents. The trend towards rapid-release formulations that provide quick relief for acute conditions is also bolstering demand for ODT excipients within this segment. As pharmaceutical companies focus on patient-centric strategies, the role of excipients in developing effective ODT formulations is expected to grow significantly.

Nutraceuticals:

The nutraceutical industry has witnessed a marked rise in the adoption of orally disintegrating tablets as a preferred dosage form, appealing to consumers seeking convenient and effective health supplements. ODT formulations facilitate rapid absorption of active ingredients, thereby enhancing their bioavailability and allowing for improved health outcomes. The increasing consumer awareness about the benefits of nutraceuticals, coupled with the demand for functional foods and dietary supplements, is driving the growth of this segment. As the market for nutraceuticals continues to expand, the demand for specialized excipients tailored for ODT formulations is expected to increase, presenting significant growth opportunities for manufacturers.

Cosmetics:

In the cosmetics sector, the use of orally disintegrating tablets is emerging as an innovative approach for delivering active ingredients such as vitamins and minerals. These formulations not only provide a convenient method of supplementing beauty-related nutrients but also enhance the bioavailability of the active ingredients. The trend towards more efficient and effective cosmetic products is fueling the demand for ODT excipients in this sector. As consumers increasingly seek multifunctional products that address beauty and health concerns, the potential for ODT formulations in cosmetics continues to grow, presenting new avenues for excipient manufacturers.

Others:

In addition to pharmaceuticals, nutraceuticals, and cosmetics, other industries are exploring the potential of orally disintegrating tablet formulations to deliver active ingredients effectively. This segment includes applications in veterinary medicine and specialized supplements for specific health conditions. The versatility of ODT formulations allows for their adaptation across various industries, expanding market opportunities. As new applications for orally disintegrating tablets are identified, the demand for excipients tailored to these unique requirements is expected to rise significantly, highlighting the adaptability and growth potential of the market.

By Formulation

Fast Disintegrating Tablets:

Fast disintegrating tablets are designed to dissolve quickly in the mouth without the need for water, making them ideal for patients who have difficulty swallowing traditional tablets. This formulation is particularly appealing in the pharmaceutical sector, where quick onset of action is often desired. The demand for fast disintegrating tablets is aligned with consumer preferences for convenience and ease of administration, driving the growth of this segment significantly. ODT excipients, including superdisintegrants and sweeteners, play a crucial role in ensuring the effectiveness of these formulations, thereby enhancing their market presence.

Mouth Dissolving Films:

Mouth dissolving films are an innovative alternative to traditional dosage forms, providing a discreet and convenient way to administer medications and supplements. These films dissolve on the mucosal membranes in the mouth, allowing for rapid absorption of the active ingredients. The rising popularity of mouth dissolving films in both pharmaceutical and nutraceutical applications is contributing to the growth of this segment. The development of specialized excipients that enhance the solubility and stability of these films is critical for their success in the market, creating opportunities for excipient manufacturers to innovate.

Orally Disintegrating Capsules:

Orally disintegrating capsules represent a unique dosage form that combines the benefits of traditional capsules and ODTs. These capsules dissolve quickly in the mouth, offering a fast-acting alternative for patients who prefer capsules over tablets. The flexibility to formulate various active ingredients into orally disintegrating capsules has made them increasingly popular, particularly in the nutraceutical sector. The demand for this formulation type continues to grow as consumers seek convenient and effective delivery methods for health supplements and medications, driving the need for ODT excipients.

Others:

Other formulations in the orally disintegrating tablet market include hybrid forms that may combine elements from the aforementioned categories. These formulations are designed to meet specific consumer needs and preferences, such as tailored release profiles or unique delivery mechanisms. The flexibility in formulation allows manufacturers to innovate and cater to diverse market demands, thus expanding the overall market for ODT excipients. As research and development efforts continue to yield new formulation options, the "others" segment is expected to see substantial growth.

By Functionality

Disintegration:

The disintegration functionality of excipients is fundamental to the performance of orally disintegrating tablets, as it dictates the rate at which the tablet breaks down after administration. The effectiveness of superdisintegrants in promoting rapid disintegration is key to ensuring that the active ingredients are released quickly and efficiently for absorption. This functionality is particularly important in the pharmaceutical sector, where fast action is often desired. As the demand for rapid-release formulations grows, excipients that enhance disintegration will continue to play a critical role in market development.

Taste Masking:

Taste masking is an essential functionality for orally disintegrating tablets, particularly in the pharmaceutical and nutraceutical industries, where many active ingredients have unpleasant flavors. Excipients designed for taste masking improve patient compliance by enhancing the palatability of medications. The demand for effective taste masking solutions is driving innovation in the development of excipients that can effectively mask the taste while maintaining the stability and bioavailability of the drug. As consumer preferences shift towards more pleasant-tasting options, the importance of taste-masking excipients in the ODT market will continue to grow.

Stability:

Stability is a crucial functionality for orally disintegrating tablet excipients, ensuring that the formulation retains its efficacy and integrity over its shelf life. Excipients that contribute to the stability of ODTs are essential in preventing degradation of active ingredients due to environmental factors such as moisture and temperature. As the pharmaceutical industry places a greater emphasis on product quality and shelf life, the demand for stability-enhancing excipients is expected to rise. Manufacturers will continue to focus on developing excipients that provide robust stability without compromising the performance of the ODTs.

Solubility Enhancement:

Solubility enhancement excipients are vital for improving the bioavailability of poorly soluble active pharmaceutical ingredients in orally disintegrating tablets. These excipients facilitate faster dissolution and absorption, ensuring that patients receive the intended therapeutic effects more rapidly. The increasing prevalence of poorly soluble drugs in the pharmaceutical pipeline is driving the demand for solubility-enhancing excipients, making them a significant segment within the ODT market. As research continues to uncover new techniques and materials for enhancing solubility, this functionality will remain critical for excipient manufacturers.

Others:

Other functionalities of ODT excipients may include film-forming properties, binding capabilities, and moisture sorption control, contributing to the overall performance and efficacy of the tablets. Manufacturers are increasingly focusing on developing multifunctional excipients that can fulfill multiple roles within a single formulation, providing enhanced efficiency in the production process. This trend towards multifunctionality is expected to drive innovation and growth in the ODT excipient market, as companies seek to create products that meet the evolving needs of consumers and pharmaceutical manufacturers.

By Region

The North American region holds a significant share of the orally disintegrating tablet excipient market, driven by the presence of prominent pharmaceutical companies and a robust healthcare infrastructure. The increasing prevalence of chronic diseases, coupled with a growing patient population that demands convenient medication forms, fuels the demand for ODTs. The North American market is projected to grow at a CAGR of 6.7% during the forecast period, indicating continued expansion in line with innovation in formulation technologies and patient-centric solutions. Additionally, the rising trend of self-medication among consumers further boosts market growth, as ODTs offer a simple and effective method of medication administration.

Europe is also poised for substantial growth in the orally disintegrating tablet excipient market, spurred by the increasing focus on research and development by pharmaceutical companies and the growing consumer demand for innovative drug delivery systems. The region benefits from a well-established pharmaceutical industry and a progressive regulatory environment that supports the development and approval of novel dosage forms. The European market is expected to witness a steady growth rate, with rising investments in R&D and an increasing emphasis on improving patient compliance, particularly among the elderly and pediatric populations. Furthermore, the expanding nutraceutical sector within Europe adds an additional layer of demand for ODT excipients, highlighting the region’s potential for market growth.

Opportunities

The opportunities in the orally disintegrating tablet excipient market are abundant, particularly with the ongoing advancements in excipient technology. As pharmaceutical companies increasingly recognize the benefits of ODTs for enhancing patient compliance, the demand for innovative excipients that facilitate better disintegration and solubility continues to rise. This trend is creating significant opportunities for excipient manufacturers to collaborate with pharmaceutical companies in developing customized solutions that meet specific formulation requirements. Moreover, the growing interest in personalized medicine represents a key opportunity, as tailored ODT formulations can be designed to cater to individual patient needs, further driving market growth.

Additionally, the expansion of the nutraceutical market presents further opportunities for ODT excipient manufacturers. As consumers seek convenient and effective delivery methods for health supplements, the demand for ODT formulations in this sector is increasing. Manufacturers can explore partnerships with nutraceutical companies to develop innovative products that meet the growing consumer demand for health and wellness solutions. Furthermore, the rising popularity of online retail channels provides a platform for excipient manufacturers to reach a broader audience, allowing them to tap into emerging markets and expand their customer base effectively.

Threats

Despite the promising growth prospects of the orally disintegrating tablet excipient market, certain threats could potentially hinder progress. Regulatory challenges remain a significant concern, particularly as pharmaceutical companies navigate varying regulations across different regions. Compliance with stringent quality and safety standards can impose additional costs and complexity for manufacturers, potentially limiting market entry for smaller players. Furthermore, the emergence of alternative drug delivery systems, such as injectable formulations or nanotechnology-based approaches, could pose competition for ODTs, impacting demand for excipients designed specifically for these applications. Manufacturers must remain vigilant and adaptable to address these challenges and maintain market relevance.

Another potential restraining factor for the ODT excipient market is the rising cost of raw materials used in excipient production. Fluctuations in the prices of key components, such as polymers and other excipient materials, could lead to increased production costs, affecting profitability for manufacturers. Additionally, supply chain disruptions, particularly in the wake of global events such as pandemics or geopolitical tensions, could impact the availability and pricing of essential excipients. Manufacturers need to focus on optimizing their supply chains and exploring alternative sourcing strategies to mitigate these risks and ensure a stable production environment.

Competitor Outlook

• JRS PHARMA
• FMC Corporation
• Roquette Frères
• Ashland Global Holdings Inc.
• Evonik Industries AG
• Colorcon
• Merck KGaA
• Aceto Corporation
• DuPont de Nemours, Inc.
• Dow Chemical Company
• Signet Chemical Corporation
• DMV International
• HPC Healthline
• Pharma Excipients
• Lubrizol Corporation

The competitive landscape of the orally disintegrating tablet excipient market is characterized by the presence of several key players who are actively engaged in research and development to innovate and enhance their product offerings. Companies like JRS PHARMA and Roquette Frères are recognized for their extensive portfolios of excipients tailored specifically for the ODT market, as well as their commitment to high-quality manufacturing practices. The competitive dynamics are influenced by the growing emphasis on patient-centric formulations, driving these companies to invest in R&D to develop excipients that facilitate rapid disintegration and enhanced bioavailability. Additionally, the need for superior taste-masking and stability solutions is prompting collaborations between excipient manufacturers and pharmaceutical companies to create customized formulations that meet specific market needs.

FMC Corporation and Ashland Global Holdings Inc. are also notable players in this market, leveraging their expertise in polymer science to develop innovative excipients that address the challenges associated with ODT formulations. These companies are focusing on creating multifunctional excipients that not only enhance disintegration but also provide stability and taste-masking functionalities. Furthermore, the increasing adoption of advanced manufacturing techniques, such as continuous manufacturing processes, is reshaping the competitive landscape, allowing companies to improve production efficiency and reduce costs. As the market evolves, these key players continue to refine their strategies to maintain a competitive edge in the growing ODT excipient market.

Emerging players, such as Colorcon and Merck KGaA, are also making significant strides in the orally disintegrating tablet excipient space, capitalizing on the growing demand for innovative formulation solutions. Their focus on developing specialized excipients that cater to the unique requirements of ODT formulations positions them favorably within the market. Additionally, these companies are actively pursuing partnerships and collaborations with pharmaceutical manufacturers to expand their reach and accelerate the adoption of their products in the ODT sector. As the market landscape becomes increasingly competitive, successful players will need to prioritize innovation, quality, and strategic alliances to thrive in this dynamic environment and capitalize on the growth opportunities presented by the evolving demands of the healthcare sector.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Colorcon
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 JRS PHARMA
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Merck KGaA
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 HPC Healthline
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 FMC Corporation
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Aceto Corporation
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 DMV International
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Pharma Excipients
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Dow Chemical Company
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Evonik Industries AG
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Lubrizol Corporation
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Roquette Frères
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 DuPont de Nemours, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Signet Chemical Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Ashland Global Holdings Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Orally Disintegrating Tablet Excipient Sales Market, By Type
    • 6.1.1 Superdisintegrants
    • 6.1.2 Binders
    • 6.1.3 Fillers
    • 6.1.4 Lubricants
    • 6.1.5 Sweeteners
  • 6.2 Orally Disintegrating Tablet Excipient Sales Market, By End Use
    • 6.2.1 Pharmaceuticals
    • 6.2.2 Nutraceuticals
    • 6.2.3 Cosmetics
    • 6.2.4 Others
  • 6.3 Orally Disintegrating Tablet Excipient Sales Market, By Formulation
    • 6.3.1 Fast Disintegrating Tablets
    • 6.3.2 Mouth Dissolving Films
    • 6.3.3 Orally Disintegrating Capsules
    • 6.3.4 Others
  • 6.4 Orally Disintegrating Tablet Excipient Sales Market, By Functionality
    • 6.4.1 Disintegration
    • 6.4.2 Taste Masking
    • 6.4.3 Stability
    • 6.4.4 Solubility Enhancement
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Orally Disintegrating Tablet Excipient Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Orally Disintegrating Tablet Excipient Sales market is categorized based on

By Type

• Superdisintegrants
• Binders
• Fillers
• Lubricants
• Sweeteners

By End Use

• Pharmaceuticals
• Nutraceuticals
• Cosmetics
• Others

By Formulation

• Fast Disintegrating Tablets
• Mouth Dissolving Films
• Orally Disintegrating Capsules
• Others

By Functionality

• Disintegration
• Taste Masking
• Stability
• Solubility Enhancement
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• JRS PHARMA
• FMC Corporation
• Roquette Frères
• Ashland Global Holdings Inc.
• Evonik Industries AG
• Colorcon
• Merck KGaA
• Aceto Corporation
• DuPont de Nemours, Inc.
• Dow Chemical Company
• Signet Chemical Corporation
• DMV International
• HPC Healthline
• Pharma Excipients
• Lubrizol Corporation